AstraZeneca PLC Director/PDMR Shareholding (7348P)
14 February 2023 - 1:01AM
UK Regulatory
TIDMAZN
RNS Number : 7348P
AstraZeneca PLC
13 February 2023
13 February 2023 14:01 GMT
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that, on 9 February
2023, an award of the Company's ordinary shares of $0.25 each
(Ordinary Shares) under the AstraZeneca Investment Plan (AZIP)
vested to Pascal Soriot, Executive Director and Chief Executive
Officer.
The AZIP award was granted on 27 March 2015 and was subject to a
four-year performance period followed by a four-year holding period
before vesting. Application of the performance measures specified
at the time of grant resulted in 75% of the AZIP award entering the
holding period.
Following the reinvestment of dividends accrued during the
performance and holding periods and the withholding of shares to
satisfy certain tax obligations arising on vesting, Mr Soriot
acquired Ordinary Shares as detailed in the table below:
PDMR Ordinary Shares
acquired under the
AZIP
Pascal Soriot 15,187
--------------------
For tax purposes, the fair market value of an Ordinary Share at
vest was 10,752 pence, being the closing price on the last trading
day preceding the vesting.
Further details are set out in the attached notification, made
in accordance with the requirements of the EU Market Abuse
Regulation (since it forms part of UK law pursuant to the European
Union (Withdrawal) Act 2018).
Details of the person discharging managerial responsibilities
1 / person closely associated
a) Name Pascal Soriot
-------------------------- -----------------------------------------
Reason for the notification
2
---------------------------------------------------------------------
a) Position/status Chief Executive Officer
-------------------------- -----------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- -----------------------------------------
Details of the issuer, emission allowance market participant,
3 auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name AstraZeneca PLC
-------------------------- -----------------------------------------
b) LEI PY6ZZQWO2IZFZC3IOL08
-------------------------- -----------------------------------------
Details of the transaction(s): section to be repeated
4i for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
---------------------------------------------------------------------
a) Description of the Ordinary Shares of US$0.25 each in
financial instrument, AstraZeneca PLC
type of instrument
Identification code GB0009895292
-------------------------- -----------------------------------------
b) Nature of the transaction Acquisition of Ordinary Shares pursuant
to a vesting under the AstraZeneca
Investment Plan, for nil consideration.
-------------------------- -----------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
0 15,187
----------
-------------------------- -----------------------------------------
d) Aggregated information Not applicable - single transaction
- Aggregated volume
- Price
-------------------------- -----------------------------------------
e) Date of the transaction 9 February 2023
-------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- -----------------------------------------
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development, and commercialisation of prescription medicines in
Oncology, Rare Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and follow the
Company on Twitter @AstraZeneca .
Contacts
For details on how to contact the Investor Relations Team,
please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHUORAROUUUAAR
(END) Dow Jones Newswires
February 13, 2023 09:01 ET (14:01 GMT)
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2024 to May 2024
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2023 to May 2024